Good news for the roughly 50 percent of psoriasis sufferers whose current treatment fails to control their chronic itching — a novel therapy has been re- ported by researchers at Temple University. Instead of indirectly combatting the itching through steroid creams that reduce skin inflammation, their drug goes right to the specific cause of the itch. The new cream, only called CT327, inhibits TrkA kinase, a compound responsible for pruritis (itching).
In the Temple research study there was a 60 per- cent reduction in itching. The therapy was safe with few side effects.